150,000 patient RWE study initiated to evaluate Cologuard
- Colorectal cancer, the second highest cancer killer in the US, can be detected by Cologuard; which has been shown to be 92% sensitive to colorectal cancer and 62% sensitive to high-risk pre-cancer patients.
- Cologuard is the only at-home colorectal cancer screening test approved by the FDA, and yet approximately 40% of the eligible patients aren’t up-to-date with the screening guidelines.
- This study aims to demonstrate the clinical effectiveness of Cologuard and help to establish it as the standard of care in colorectal cancer screening.
Click here to read the source article
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.